PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться
  1. Биоэквивалентность. ANOVA. Часть I.
  2. Биоэквивалентность. ANOVA. Часть II.
  3. Биоэквивалентность. ANOVA. Пример.
  4. Phoenix WinNonlin проект подтверждения метода.
  5. Биоэквивалентность. Расчет выборки.
  6. Пример расчета выборки с помощью итеративной процедуры.
  7. Пример расчета pooled CV и доверительного интервала для CV.
  8. Фармакокинетика. Основные понятия.
  9. Фармакокинетика. Основные понятия. Пример расчета ФК параметров.
  10. Phoenix WinNonlin проект подтверждения примера расчета ФК параметров.
  11. Планирование клинического исследования.
  12. Биоэквивалентность. ANOVA. Часть III.
  13. Таблица данных для тестового расчета.

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

20180130 153014
20170730 121344
20170730 175202
20180130 171107
DJI 0065
IMG-20170806-WA0044
  • Influenza (Flu) Antiviral Drugs and Related Information
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • Emergency Use Authorizations for Drugs and Non-Vaccine Biological Products
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • From Our Perspective
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • CDER Pilot Grant Program: Standard Core Clinical Outcome Assessments (COAs) and their Related Endpoints
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • Competitive Generic Therapy Approvals
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • Human medicines European public assessment report (EPAR): Livmarli, maralixibat chloride, Date of authorisation: 09/12/2022, Revision: 9, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-12
  • Completed PDUFA VI Deliverables
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • How Modeling Was Used to Support the FDA Approval of a Topical Generic Drug Product
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • FDA Adverse Event Reporting System (FAERS) Electronic Submissions
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • Office of Infectious Diseases Research Activities
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • How physicians interpret information about prescription drugs in scientific publications vs. promotional pieces
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • Annual Licensure Reporting by Wholesale Drug Distributors and Third-Party Logistics Providers
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • Check Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • Human medicines European public assessment report (EPAR): Velsipity, etrasimod, Date of authorisation: 16/02/2024, Revision: 3, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-12
  • Patient-Focused Drug Development: Workshop #2 to Discuss Methodologic and Other Challenges Related to Patient Experience Data - 09/18/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-11 By FDA
Предыдущие записи
Тема: Scaffold от Danny Cooper.